Isofol Medical AB (OSTO:ISOFOL) Research & Development: kr10.17 Mil (TTM As of Mar. 2026)


OSTO:ISOFOL Isofol Medical AB OSTO:ISOFOL
30 GF Score
Price kr0.71
! 2 Warning Signs
View Full Analysis

What is Isofol Medical AB Research & Development?

Isofol Medical AB OSTO:ISOFOL +1.28% 30 Research & Development is kr10.17 Mil as of Mar. 2026. GuruFocus rates OSTO:ISOFOL with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Isofol Medical AB's Research & Development for the three months ended in Mar. 2026 was kr10.17 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr10.17 Mil.

Isofol Medical AB  (OSTO:ISOFOL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Isofol Medical AB Research & Development Related Terms

Isofol Medical AB Research & Development Historical Data

* Premium members only.

The historical data trend for Isofol Medical AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Isofol Medical AB Research & Development Chart

Isofol Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Isofol Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.68 0.00 0.00 0.00 10.17
OSTO:ISOFOL
30GF Score
Isofol Medical AB OSTO:ISOFOL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Isofol Medical AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr10.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr10.17 Mil mean?
Isofol Medical AB (OSTO:ISOFOL) has a Research & Development of kr10.17 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Isofol Medical AB and its competitors.
Is Isofol Medical AB's Research & Development too high?
Isofol Medical AB's current Research & Development is kr10.17 Mil. Overall, Isofol Medical AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Isofol Medical AB's Research & Development compare to VRTX and REGN?
Isofol Medical AB's Research & Development of kr10.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Isofol Medical AB and its competitors. Isofol Medical AB's current Research & Development is kr10.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Isofol Medical AB stock overvalued right now?
Isofol Medical AB (OSTO:ISOFOL) has a current Research & Development of kr10.17 Mil. The current Research & Development is kr10.17 Mil. Isofol Medical AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Isofol Medical AB (OSTO:ISOFOL), the current Research & Development is kr10.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Isofol Medical AB Business Description

Address Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
30GF Score

Get the complete analysis for OSTO:ISOFOL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.71
Price